CARISEL Interim Results: Acceptability, Appropriateness, Feasibility, Barriers, and Facilitators of LA CAB + RPV

Preguntas respondidas por expertas de Clinical Care Options (CCO) sobre las mejores prácticas para cambiar el TAR en pacientes suprimidos en México.

Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Released: May 17, 2022

Introductory Case

Question and Answer Session

Expert selections of data for state-of-the-art switch strategies in virologically suppressed patients.

Joseph J. Eron, Jr., MD
Program Director Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director Paul E. Sax, MD Released: May 6, 2022

Slides from CCO: Discussion of key data and recommendations for the use of novel therapies for HIV treatment and prevention

Cristina Mussini, MD William R. Short, MD, MPH, AAHIVS Released: April 15, 2022

Expert selections of cutting-edge HIV data, including the latest on long-acting therapies and pre-exposure prophylaxis

Joseph J. Eron, Jr., MD
Program Director Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director Darcy Wooten, MD Released: March 25, 2022